



Financial Tear Sheet

Corporate Profile

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com (<http://www.alkermes.com>).

IR Contacts

Sandy Coombs
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6377
E-mail: Sandra.Coombs@alkermes.com (<mailto:Sandra.Coombs@alkermes.com>)

Eva Stroynowski
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6823
E-mail: eva.stroynowski@alkermes.com (<mailto:eva.stroynowski@alkermes.com>)

Stock Performance

ALKS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$67.26
Change (%)	3.51 (5.51%) ▲
Volume	2,687,488
52 Week Low	\$46.42
Market Cap	\$10,502,270,057
Rolling EPS	-1.03
PE Ratio	N/A
Shares Outstanding	156,144,366
Data as of 02/16/18 4:00 p.m. ET	



Recent Headlines & Events

02/14/18 - 8:00 a.m.
[Alkermes Appoints Shane Cooke to Board of Directors \(phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2332384\)](#)

02/14/18 - 7:00 a.m.
[Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018 \(phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2332362\)](#)

02/07/18 - 4:01 p.m.
[Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results \(phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2331037\)](#)

There are currently no events scheduled.

Mean Recommendation: 2.5

Unable to fulfill request.



Sell Strong Buy

SEC Filings

Year Filter

All Years

Filing Date	Form
02/16/18	10-K (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTwNjUxMzMmc3Vic2lkPTU3&ListAll=1&sXBRL=1)
02/14/18	8-K (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTwNjA5MzEmc3Vic2lkPTU3&ListAll=1)
02/14/18	SC 13G/A (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTwNTY3ODMmc3Vic2lkPTU3&ListAll=1)
02/14/18	8-K (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTwNTMzNjUmc3Vic2lkPTU3&ListAll=1)


Corporate Governance

Richard F. Pops	Chairman and Chief Executive Officer
Shane Cooke	President
Kathryn L. Biberstein	Senior Vice President, Chief Legal Officer and Chief Compliance Officer, and Secretary Alkermes plc
Madeline D. Coffin	Vice President, Human Resources
Elliot W. Ehrich, M.D.	Executive Vice President, Research and Development, and Chief Medical Officer
James M. Frates	Senior Vice President and Chief Financial Officer
Georgianna Harris, Ph.D.	Vice President, Regulatory Affairs
Blair C. Jackson	Vice President, Business Development
Michael J. Landine	Senior Vice President, Corporate Development
Mark Namchuk, Ph.D.	Senior Vice President, Research, Pharmaceutical and Nonclinical Development
Peter Norman	Vice President, Government Policy and Affairs
Rebecca J. Peterson	Senior Vice President, Corporate Communications
Gordon G. Pugh	Senior Vice President, Chief Operating Officer and Chief Risk Officer
Srdjan Stankovic, M.D., MSPH	Senior Vice President, Clinical Development & Medical Affairs
Mark Steibach	Senior Vice President, Chief Commercial Officer

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	0	.00	0.0	0
Mutual Fund	0	.00	0.0	0
Insider *	0	.00	0.0	0

*Insider values reflect direct beneficial ownership.

Powered by  Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed